NCT02556450 - Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure | Biotech Hunter

Enrollment

528

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

January 31, 2019

Conditions

Heart Failure

Interventions

DRUG

Spironolacton

Administration of Spironolacton 25 mg per day

Trial Locations (9)

Santa Margherita Hospital, Cortona

CHU de Nancy, Nancy

Hopital Sud Francilien, Corbeil-Essonnes

Charite Universitatsmedizin Berlin, Kardiologie, Berlin

St, Michaels Hospital, Dublin

Maastricht University Medical Center, Maastricht

Queen Elizabeth University Hospital, Glasgow

Castle Hill Hospital, Hull

Central Manchester University Hospitals NHS, Manchester